AbbVie Inc. Stock
€220.70
Your prediction
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 0.180% | 6.618% | 20.535% | 36.911% | 12.373% | 78.704% | 128.847% |
| BioMarin Pharmaceutical Inc. | 1.400% | 0.673% | 7.461% | 6.672% | -0.118% | -35.986% | -28.212% |
| Biogen Inc. | -2.510% | 4.936% | 11.653% | 67.307% | 23.150% | -29.295% | -37.317% |
| Zoetis Inc. A | 1.810% | -7.523% | -4.499% | -52.844% | -40.686% | -59.632% | -60.163% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.
Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.
Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.
Comments
News
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
AbbVie's (NYSE: ABBV) financial results have been strong recently, largely thanks to its key growth drivers, Skyrizi and Rinvoq. However, both of these immunosuppressants will lose patent
3 No-Brainer Dividend Stocks to Buy Right Now
With the S&P 500 looking historically expensive at 31 times earnings, it's a good time to buy a few defensive dividend stocks to hedge against a market crash. These stocks might also swoon during a
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
When a stock hits a new 52-week high, it can be a sign that things are going well for the business and that investors are recognizing some encouraging value. However, it also means that the stock